Stocksigma LogoStocksigma Logo

Balaxi Pharmaceuticals Reports Strong Q2 FY27 Earnings Growth

Balaxi Pharmaceuticals reported strong consolidated Q2 FY27 results on 12th Nov'26, with revenue from operations growing 44.85% YoY to ₹8,137.23 lakh

Balaxi Pharmaceuticals Reports Strong Q2 FY27 Earnings Growth

Balaxi Pharmaceuticals Ltd · Press Release · 13 Nov 2026, 2:20 am

Balaxi Pharmaceuticals Reports Strong Q2 FY27 Earnings Growth Balaxi Pharmaceuticals reported strong consolidated Q2 FY27 results on 12th Nov'26, with revenue from operations growing 44.85% YoY to ₹8,137.23 lakh. EBITDA surged 338.19% YoY to ₹512.07 lakh as EBITDA margin expanded 421 bps to 6.29%. Net profit rose 450.29% YoY to ₹115.01 lakh, with diluted EPS increasing to ₹0.21. For H1 FY27, revenue reached ₹16,205.40 lakh (up 27.68% YoY) and PAT stood at ₹244.76 lakh (up 390.30% YoY). The company added 31 new registrations and operationalized its Jadcherla formulation facility.

Original exchange filing (PDF)

More announcements from Balaxi Pharmaceuticals Ltd

All Balaxi Pharmaceuticals Ltd announcements